Although the triple CFTR-modulator therapy has profoundly changed the CF scenario, significantly improving clinical parameters and the life quality of CF patients, the extent to which these therapies may reduce lung infections and restore a healthy-associated lung microbiome has yet to be fully determined [2]. This evidence concerns the gene CFTR and cystic fibrosis.